Entry Inhibitors of RNA Viruses

Edeildo   F. da   Silva-Júnior
[1] 
Payne, S. Introduction to RNA Viruses.Viruses; Elsevier, 2017, pp. 97-105.
[http://dx.doi.org/10.1016/B978-0-12-803109-4.00010-6] 
[2] 
Yamauchi, Y.; Helenius, A. Virus Entry at a Glance. J. Cell Sci.,  2013, 126(Pt 6), 1289-1295.
[http://dx.doi.org/10.1242/jcs.119685] [PMID:  23641066s] 
[3] 
Hu, Z.; Rolt, A.; Hu, X.; Ma, C.D.; Le, D.J.; Park, S.B.; Houghton, M.; Southall, N.; Anderson, D.E.; Talley, D.C.; Lloyd, J.R.; Marugan, J.C.; Liang, T.J. Chlorcyclizine Inhibits Viral Fusion of Hepatitis C Virus Entry by Directly Targeting HCV Envelope Glycoprotein 1. Cell Chem. Biol.,  2020, 27(7), 780-792.e5.
[http://dx.doi.org/10.1016/j.chembiol.2020.04.006] [PMID:  32386595] 
[4] 
Hung, T.; Jassey, A.; Liu, C.; Lin, C-J.; Lin, C-C.; Wong, S.H.; Wang, J.Y.; Yen, M.; Lin, L. Berberine Inhibits Hepatitis C Virus Entry by Targeting the Viral E2 Glycoprotein. Phytomedicine,  2019, 53, 62-69.
[http://dx.doi.org/10.1016/j.phymed.2018.09.025] [PMID:  30668413] 
[5] 
Silva, L.R.; Rodrigues, É.E. da S.; Taniele-Silva, J.; Anderson, L.;  Araújo-Júnior, J.X.; de Bassi, Ê.J.;  Silva-Júnior, E.F. da Targeting Chikungunya Virus Entry: Alternatives for New Inhibitors in Drug Discovery. Curr. Med. Chem.,  2022, 29(4), 612-634.
[http://dx.doi.org/10.2174/0929867328666210623165005] [PMID:  34165405] 
[6] 
Müller, P.; Maus, H.; Hammerschmidt, S.J.; Knaff, P.; Mailänder, V.; Schirmeister, T.; Kersten, C. Interfering with Host Proteases in SARS-CoV-2 Entry as a Promising Therapeutic Strategy. Curr. Med. Chem.,  2022, 29(4), 635-665.
[http://dx.doi.org/10.2174/0929867328666210526111318] [PMID:  34042026] 
[7] 
Kushwaha, P.K.; Kumari, N.; Nayak, S.; Kishor, K.; Sharon, A. Structural Basis for the Understanding of Entry Inhibitors Against SARS Viruses. Curr. Med. Chem.,  2022, 29(4), 666-681.
[http://dx.doi.org/10.2174/0929867328666210514122418] [PMID:  33992054] 
[8] 
Lin, H.; Cherukupalli, S.; Feng, D.; Gao, S.; Kang, D.; Zhan, P.; Liu, X. SARS-CoV-2 Entry Inhibitors Targeting Virus-ACE2 or Virus-TMPRSS2 Interactions. Curr. Med. Chem.,  2022, 29(4), 682-699.
[http://dx.doi.org/10.2174/0929867328666210420103021] [PMID:  33881969] 
[9] 
Pu, J.; Zhou, J.T.; Liu, P.; Yu, F.; He, X.; Lu, L.; Jiang, S. Viral Entry Inhibitors Targeting Six-Helical Bundle Core against Highly Pathogenic Enveloped Viruses with Class I Fusion Proteins. Curr. Med. Chem.,  2022, 29(4), 700-718.
[http://dx.doi.org/10.2174/0929867328666210511015808] [PMID:  33992055] 
[10] 
Gallo, F.N.; Enderle, A.G.; Pardo, L.A.; Leal, E.S.; Bollini, M. Challenges and Perspectives in the Discovery of Dengue Virus Entry Inhibitors. Curr. Med. Chem.,  2022, 29(4), 719-740.
[http://dx.doi.org/10.2174/0929867328666210521213118] [PMID:  34036904] 
Cite As
Current Medicinal Chemistry

Entry Inhibitors of RNA Viruses
